Teva Pharmaceutical Industries Ltd. et al: Statement of Charges

Statement of Charges and Notice of Hearing regarding the “false and misleading marketing” of opiod products in the matter of Teva Pharmaceutical Industries Ltd., of Israel; Teva Pharmaceuticals USA Inc., of Pennsylvania; Cephalon Inc., of Delaware; Watson Laboratories Inc., of Nevada; Actavis Pharma Inc., of Delaware; Actavis LLC, of Delaware; Actavis Elizabeth LLC, of Delaware; Allergan Plc, of Ireland, and Allergan Finance LLC, of Nevada, before the New York State Department of Financial Services.

- You’re only seeing part of this content
  
  To view the entire article or download the document, subscribe today.
  
  – Offshore Courts: 29,000+ court cases (Bahamas, Bermuda, BVI, Cayman Islands)
  – Investigative Articles: 4,500+ in-depth articles, including fraud exposés
  – MLATs – Criminal: 1,400+ MLATs on global criminal investigations
  – Ch. 15 – Insolvencies: Monitored daily
  – Foreign Discovery: Applications for foreign discovery filed in the USA, monitored daily
  – Regulatory Actions: Global regulatory actions, fines, and bans, monitored daily
  – And More: Criminal indictments, extraditions, winding-up petitions, and more
  
  Unlimited access for less than $3/day.
  
  Cancel anytime.
  
  SUBSCRIBE
- SIGN IN
  
  Forgot your password?

Pages: 30

Date: August 17, 2020

Defendant(s)/Respondent(s): Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA Inc., Cephalon Inc., Watson Laboratories Inc., Actavis Pharma Inc., Actavis LLC, Actavis Elizabeth LLC, Allergan Plc, Allergan Finance LLC

Plaintiff(s)/Applicant(s): New York State Department of Financial Services

Case Number: Xx Xx Xx

Topic: Regulatory

Allegation: Fraud

Topics

Keywords

Actavis Elizabeth LLC Actavis LLC Actavis Pharma Inc. Allergan Finance LLC Allergan Plc

Cephalon Inc. New York State Department of Financial Services Teva Pharmaceutical Industries Ltd. Teva Pharmaceuticals USA Inc. Watson Laboratories Inc.

[ 5 more... ] [ top 5 ]

BECOME A SUBSCRIBER

Daily red flags in high-value international finance

Unlimited access. No contracts. Cancel anytime.